Alcon AG (ALC)vsNephros Inc (NEPH)
ALC
Alcon AG
$66.03
-0.78%
HEALTHCARE · Cap: $34.08B
NEPH
Nephros Inc
$4.47
-1.11%
HEALTHCARE · Cap: $44.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Alcon AG generates 52313% more annual revenue ($10.86B vs $20.72M). NEPH leads profitability with a 8.4% profit margin vs 5.9%. NEPH trades at a lower P/E of 25.4x. NEPH earns a higher WallStSmart Score of 58/100 (C).
ALC
Buy51
out of 100
Grade: C-
NEPH
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.0%
Fair Value
$65.08
Current Price
$66.03
$0.95 premium
Margin of Safety
+12.6%
Fair Value
$4.62
Current Price
$4.47
$0.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 36.2% year-over-year
Earnings expanding 450.0% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 20.2%
Areas to Watch
ROE of 3.8% — below average capital efficiency
5.9% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Moderate valuation
Smaller company, higher risk/reward
ROE of 7.3% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALC
The strongest argument for ALC centers on Price/Book, Debt/Equity. PEG of 1.27 suggests the stock is reasonably priced for its growth.
Bull Case : NEPH
The strongest argument for NEPH centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 36.2% demonstrates continued momentum.
Bear Case : ALC
The primary concerns for ALC are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 53.8x leaves little room for execution misses.
Bear Case : NEPH
The primary concerns for NEPH are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
ALC profiles as a value stock while NEPH is a hypergrowth play — different risk/reward profiles.
NEPH carries more volatility with a beta of 1.56 — expect wider price swings.
NEPH is growing revenue faster at 36.2% — sustainability is the question.
ALC generates stronger free cash flow (414M), providing more financial flexibility.
Bottom Line
NEPH scores higher overall (58/100 vs 51/100) and 36.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alcon AG
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.
Visit Website →Nephros Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?